Clinical trials: Primary Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03785587
- Testing
- Sofpironium Bromide Gel, 15%
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Botanix Pharmaceuticals
Primary Axillary Hyperhidrosis
A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits, hands, and feet) affects approximately 4.8% of the US population and is believed to be caused by an overactive cholinergic response of…
- Trial name
- NCT03627468
- Testing
- Sofpironium Bromide Gel, 5%, Sofpironium Bromide Gel, 15%
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- Botanix Pharmaceuticals
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation